Lonza and CN Bio have entered into a distribution agreement where Lonza will supply a selection of hepatic cells to be prequalified by CN Bio for use in its PhysioMimix Single-and Multi-Organ MPS. The aim is to change the way human-relevant pre-clinical data is generated.
With prequalified cells, customers can avoid having to trial numerous cell types in order to be assured of finding ones that will grow and behave functionally in 3D culture and fast-track their route to generating reliable and robust data.
The use of physiologically relevant in vitro models plays an important role in driving down attrition rates and boosting the efficiency and success of drug discovery programmes. It is increasingly clear that standard 2D cell culture fails to accurately reflect the complex interactions that take place in the living body, while animal models are slow, expensive and don’t always correlate to the same interactions in humans.
Maureen Bunger, Senior Product Manager, ADME-Tox Solutions, Lonza Cell and Gene, commented: “Today’s drug discovery success is hugely dependent on performing experiments using the right biological model to best reflect in vivo environments. This new agreement with CN Bio further demonstrates Lonza’s commitment to supporting innovation and to the development of the most advanced cell models for enhanced drug discovery and development success.”
Dr Tomasz Kostrzewski, Director of Biology, CN Bio, commented: “We’re delighted to be working with Lonza, a world-leading cell supplier, to ensure that the prevalidated cells we supply for use with our PhysioMimix Single-and Multi-Organ MPS are of reliably high quality and are well-suited to culture in 3D. Using prequalified cells will save our customers valuable time and resource, further helping to accelerate their drug development journey.”